Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials-Reference-Cited by-同舟云学术

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

Published:2006-05-30 Issue:12 Volume:94 Page:1789-1796
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Ferretti G,Bria E,Giannarelli D,Felici A,Papaldo P,Fabi A,Di Cosimo S,Ruggeri E M,Milella M,Ciccarese M,Cecere F L,Gelibter A,Nuzzo C,Cognetti F,Terzoli E,Carlini P

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6603194.pdf

Reference40 articles.

1. Bailey K (1987) Inter-study differences: how should they influence the interpretation and analysis of results. Stat Med 6: 351–358

2. Berlin JA, Laird NM, Sacks HS, Chalmers TC (1989) A comparison of statistical methods for combining event rates from clinical trials. Stat Med 8: 141–151

3. Boeddinghaus IM, Dowsett M (2001) Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol 79: 85–91

4. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92: 2247–2258

5. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M (2000) Anastrozole vs tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the TARGET (Tamoxifen or Arimidex Randomised Group Efficacy and Tolerability) study. J Clin Oncol 18: 3748–3757

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triazoles in Medicinal Chemistry: Physicochemical Properties, Bioisosterism, and Application;Journal of Medicinal Chemistry;2024-05-03

2. QSAR and Molecular Docking Studies of Pyrimidine-Coumarin-Triazole Conjugates as Prospective Anti-Breast Cancer Agents;Molecules;2022-03-11

3. Management of human epidermal growth factor receptor 2–negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors;Indian Journal of Cancer;2022

4. Landmark trials in the medical oncology management of metastatic breast cancer;Seminars in Oncology;2021-06

5. Tumor-targeted Drug Delivery by Nanocomposites;Current Drug Metabolism;2020-11-20